Download presentation
Presentation is loading. Please wait.
Published byLaura Nelson Modified over 6 years ago
1
Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti–Tumor Necrosis Factor-α Agents Christine Kestens, Martijn G.H. van Oijen, Charlotte L.J. Mulder, Ad A. van Bodegraven, Gerard Dijkstra, Dirk de Jong, Cyriel Ponsioen, Bas A.C. van Tuyl, Peter D. Siersema, Herma H. Fidder, Bas Oldenburg Clinical Gastroenterology and Hepatology Volume 11, Issue 7, Pages (July 2013) DOI: /j.cgh Copyright © 2013 AGA Institute Terms and Conditions
2
Figure 1 Rates of response for patients with CD treated with anti-TNFα. (A) Percentage of patients with a response treated with anti-TNFα and (B) a comparison with and without concomitant use of immunomodulators. *Response rates of IFX with and without immunomodulators were both significantly different in favor of combined treatment after 1 and 2 years. Clinical Gastroenterology and Hepatology , DOI: ( /j.cgh ) Copyright © 2013 AGA Institute Terms and Conditions
3
Figure 2 Remission in patients with CD divided by (A) type of anti-TNFα given and (B) with and without concomitant use of immunomodulators. Clinical Gastroenterology and Hepatology , DOI: ( /j.cgh ) Copyright © 2013 AGA Institute Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.